OTCMKTS:ALPMY Astellas Pharma 2/5/2024 Earnings Report $9.95 -0.02 (-0.15%) As of 03:58 PM Eastern ProfileEarnings History Astellas Pharma EPS ResultsActual EPS$0.12Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAstellas Pharma Revenue ResultsActual Revenue$2.86 billionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAstellas Pharma Announcement DetailsQuarterDate2/5/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsAstellas Pharma's next earnings date is estimated for Tuesday, July 29, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Astellas Pharma Earnings HeadlinesAstellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program"July 16, 2025 | prnewswire.comAstellas Pharma Inc. (ALPMY) Income Statement - Yahoo FinanceJuly 10, 2025 | finance.yahoo.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. July 28 at 2:00 AM | Crypto 101 Media (Ad)ALPMY Astellas Pharma Inc. - Seeking AlphaJuly 8, 2025 | seekingalpha.comAstellas Pharma Inc Analysis & Opinion (ALPMY) - Investing.comJuly 2, 2025 | investing.comAstellas Pharma’s New Study on ASP3021: A Potential Game-Changer for AMD TreatmentJune 24, 2025 | msn.comSee More Astellas Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Astellas Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astellas Pharma and other key companies, straight to your email. Email Address About Astellas PharmaAstellas Pharma (OTCMKTS:ALPMY) manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.View Astellas Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Reasons Tesla's Post-Earnings Hangover Looks Like a BuyT-Mobile Earnings Show You Why This Is a Stock to HoldAmerican Airlines Earnings Miss, But Bulls Aren’t Backing OffMeta's Q2 Earnings: Key Areas Investors Must Pay Attention ToIs Former Dividend Aristocrat AT&T a Buy After Q2 Earnings?Why Freeport-McMoRan Stock May Hit a New High After Earnings BeatMicrosoft’s AI Bet Faces a Major Test This Earnings Season Upcoming Earnings AstraZeneca (7/29/2025)Booking (7/29/2025)Mondelez International (7/29/2025)PayPal (7/29/2025)Starbucks (7/29/2025)American Tower (7/29/2025)America Movil (7/29/2025)Boeing (7/29/2025)Barclays (7/29/2025)Carrier Global (7/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
